IF Revel Pharmaceuticals' designer glucosepane-cleaving enzyme (lead biocatalyst, dose titrated to achieve ≥50% glucosepane reduction as confirmed by LC-MS/MS, administered via ex vivo bath incubation at physiological pH 7.4, 37°C) is applied to isolated tail tendon fascicles from aged (24-month-old) male C57BL/6J mice whose glucosepane load has been elevated to human-equivalent concentrations (~2,000–5,000 pmol/mg collagen) through a standardized 72-hour ex vivo D-ribose incubation protocol prior to treatment,
THEN a statistically significant reduction in tensile Young's modulus (≥20% vs. vehicle-treated aged controls), a restoration of stress-relaxation time constants toward values observed in young (3-month-old) reference tendons, and a corresponding reduction in glucosepane content quantified by LC-MS/MS will be observed,
BECAUSE:
- Glucosepane forms irreversible covalent crosslinks between lysine and arginine residues on adjacent collagen triple helices, functioning as rigid molecular tethers that restrict interfibrillar sliding — the primary mechanism of viscoelastic energy dissipation in tendon (as described in the literature review, citing Monnier et al., Gerontology, 2012, and the Acta Biomaterialia, 2014 review on collagen crosslinks and aging).
- Murine tail tendons do not accumulate glucosepane at human-equivalent concentrations within the mouse lifespan; a D-ribose ex vivo glycation step overcomes this translational gap by artificially elevating glucosepane to physiologically relevant human concentrations, creating a chemically faithful substrate for en





























